Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer

Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer

BACKGROUND/AIM: Real-world data on the clinical outcomes of first-line osimertinib treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is lacking. This study aimed to reveal the treatment outcomes and prognostic factors of osimertinib as first-line...

Full description

Bibliographic Details
Main Authors: Endo, T. (Author), Funayama, Y. (Author), Furukawa, K. (Author), Hizawa, N. (Author), Ichimura, H. (Author), Inagaki, M. (Author), Kaburagi, T. (Author), Kikuchi, N. (Author), Kikuchi, S. (Author), Koyama, N. (Author), Kurishima, K. (Author), Miyazaki, K. (Author), Nakamura, H. (Author), Numata, T. (Author), Saito, K. (Author), Sato, Y. (Author), Satoh, H. (Author), Sekine, I. (Author), Shiozawa, T. (Author), Tamura, T. (Author), Yamada, H. (Author), Yamamoto, Y. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
EGFR mutation
Lung cancer
osimertinib
PD-L1
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items